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ABSTRACT
BACKGROUND: The most common cause for the failure of external dacryocysto-
rhinostomy (DCR) surgery is the formation ofgranulation tissue at the osteotomy site
or common canaliculus.
OBJECTIVES: The aims of this study were to assess the efficacy of intraoperative
adjunctive mitomycin C (MMC) treatment in external DCR surgery and to compare
this procedure with the standard DCR procedure alone in the long term (1 year).
METHODS: In this prospective, double-masked, randomized, controlled trial,
patients with primary acquired nasolacrimal duct obstruction were randomized (using
a random number table) into 2 groups based on surgical procedure. In the MMC
group, intraoperative adjunctive MMC 0.2 mg/mL was applied to the osteotomy
site for 30 minutes. The control group underwent standard DCR procedure only. The
results of the DCR surgeries were assessed using objective findings (eg, cessation of
excessive tearing via nasolacrimal duct irrigation and the improvement in height of tear
meniscus) and subjective symptoms (asking patients to describe the degree of tearing
improvement). Both the patients and the researchers who were assessing the study
outcomes were masked to treatment group.
RESULTS: One hundred eyes of 100 Turkish patients were assessed and equally
randomized to the MMC (27 women, 23 men; mean [SD} age, 47.0 [7.6} years)
and control (26 women, 24 men; mean age, 46.6 [8.8} years) groups. The follow-
up period was not significantly different between the MMC and the control groups
(13.1 [1.l} vs 13.2 [1.4} months). Significantly more eyes in the MMC group than
the control group remained symptom-free throughout the 1-year follow-up period
(45/50 [90%} vs 33/50 [66%}; P = 0.005). Significantly more patients in the control
group than the MMC group had an improvement in symptoms at the 1-year follow-up
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(8/50 [l6%} vs 2/50 [4%} eyes; P = 0.005). Based on the patency of the drainage sys-
tem, the success rate was significantly greater in the MMC group than the control group
(48/50 [96%} vs 42/50 [84%}; P = 0.005). Based on nasolacrimal duct irrigation, signifi-
cantly fewer patients in the MMC group than the control group had an enclosed naso-
lacrimal duct (2/50 [4%} vs 8/50 [l6%}). No adverse effects (eg, abnormal nasal bleeding,
mucosal necrosis, infection) or any other surgical adverse events were observed.
CONCLUSIONS: In the management of these patients with primary acquired
nasolacrimal duct obstruction, adjunctive intraoperative MMC application with
standard DCR surgery had a significantly higher success rate than did standard
DCR surgery alone. Further large, double-masked, randomized studies are needed to
confirm these findings. (Curr Ther Res Clin Exp. 2009;70:267-273) © 2009 Excerpta
Medica Inc.
KEY WORDS: dacryocystorhinostomy, nasolacrimal duct obstruction, mito-
mycin C.
INTRODUCTION
External dacryocystorhinostomy (DCR) has a success rate of ~90% in the manage-
ment of nasolacrimal duct obstruction. 1,2 Other studies have reported success rates
from 82% to 100% with this procedure. 3- 5 Failure is frequently related to granulation
formation at the osteotomy site or common canaliculus,6,7 technical error,s or closure
of the anastomosis site. 9 Fibrous tissue and granulation formation are associated with
surgical failure because they diminish ostium size and lead to nonpatency.6,lO Efforts
should focus on inhibiting granulation tissue over the osteotomy site and anastomosed
flaps to increase the surgical success rate.
Mitomycin C (MMC), an alkalizing antibiotic, acts by inhibiting DNA-dependent
RNA synthesis and represents an alternative approach to prevent the development of
fibrous tissue formation over the osteotomy site and the anastomosed flaps.3 MMC has
been reported to inhibit excessive fibrous tissue formation subsequent to trabeculec-
tomy for glaucoma. 11 MMC may increase the surgical success rate ofDCR by prevent-
ing both a decrease in ostium size and canalicular obstruction. 4 ,5,12
Due to the potential for adverse effects (AEs), MMC is typically administered for
brief durations (2-10 minutes) at doses of 0.2 to 0.4 mg/mL. It has been reported that
0.2 mg/mL MMC administered to an osteotomy site for 30 minutes might be favor-
able to increase success rates with no significant increase in AEs. The aims of this
study were to assess the efficacy of intraoperative adjunctive MMC treatment in exter-
nal DCR surgery and to compare this procedure with the standard DCR procedure
alone in the long term (1 year).
PATIENTS AND METHODS
In this prospective, double-masked, randomized, controlled trial, patients with pri-
mary acquired nasolacrimal duct obstruction who were to undergo DCR surgery from
2005 to 2007 were divided into 2 groups based on the surgical procedure. The pa-
tients were randomized to treatment using a random number table. In the MMC
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group, intraoperative adjunctive MMC 0.2 mg/mL was applied to the osteotomy site
for 30 minutes. The control group underwent the standard DCR surgery only.
The exclusion criteria were as follows: aged < 18 or > 70 years, previous nasolac-
rimal duct surgery, morphologic or functional palpebral disorders, and secondary
causes of nasolacrimal duct obstruction.
Written informed consent was obtained from all participants prior to surgery.
Institutional review board approval was obtained from Diyarbakir Training and
Research Hospital (Diyarbakir, Turkey).
Both objective findings and subjective reports were followed up for ~ 1 year after
the surgery. Clinical assessments, including dacryocystography and endoscopic nasal
examinations, were performed throughout the follow-up period.
In both groups, the standard DCR procedure1,2 was carried out under local anes-
thesia consisting of lidocaine hydrochloride 20 mg and epinephrine 0.0125 mg/mL
Oetocain simplex®, Adeka, Izmir, Turkey) administered to the medial and lower can-
thus. Anesthesia of the nasal mucosa consisted of 2 mL cocaine 5% and adrenaline
1:100,000. An incision site of ~2 em was marked over the anterior lacrimal crest
starting just below the medial canthal tendon. The skin was incised and blunt dissec-
tion was performed until the periosteum overlying the anterior lacrimal crest was
exposed. The periosteum was incised and elevated off the lacrimal sac fossa. The os-
teotomy was created over the lacrimal sac fossa using a Kerrison punch. In every case,
the ostium was maintained at 15 x 15 mm along the superoinferior and anteroposte-
rior axes. The nasal mucosa was cut with sharp-tipped scissors to form anterior and
posterior mucosal flaps, then the posterior nasal and lacrimal sac flaps were joined
with 6-0 Vicryl sutures (Ethicon Inc., Somerville, New Jersey). In the MMC group, a
piece of 0.5 x 0.5-cm neurosurgical cottonoid with long silk strings saturated with
1 mL of MMC 0.2 mg/mL was placed over the anastomosed posterior flaps and
osteotomy site. The silk strings were left protruding from the nasal cavity. The an-
terior nasal and lacrimal sac flaps were closed with 6-0 Vicryl sutures, in addition
to closing the periosteum and the orbicularis muscle in separate layers. The skin
incision was closed with a running 6-0 Prolene suture (Ethicon Inc.). The MMC-
soaked cottonoid was removed transnasally by pulling out the silk string in the recov-
ery room after an application time of 30 minutes.
In the control group, the same surgical procedures were performed, except that
MMC and the silk cottonoid were not applied. The surgeries were performed by a
single surgeon (~.A.). There was no contact between the surgeon and the researchers
evaluating the study outcomes. The patients and the researchers were masked to the
treatment.
Gentamicin 3% and dexamethasone eyedrops were administered postoperatively
4 times daily for 1 month and oral antibiotic treatment was administered for 7 days.
Regular clinical examinations were carried out at 1 and 14 days and 1, 2, 3, 6, and
12 months postoperatively. At each visit, sterile saline was used for irrigation and the
stitches were removed 14 days postsurgery.
Recording and follow-up of AEs were performed by another surgeon (S.S.) who was
masked to treatment. AEs were evaluated by transcanalicular nasolacrimal irrigation
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and transnasal endoscopic examination. Success was defined as being asymptomatic or
having improvement in tearing and patency of drainage. At each visit, the success rate
was evaluated objectively based on the patency of irrigation and subjectively by asking
the patient about tearing.
Failure was defined as no improvement in tearing, consistency in the severity of
symptoms, or nonpatency of the nasolacrimal duct.
The t and X2 tests were used for statistical analysis. P< 0.05 was considered statisti-
cally significant.
RESULTS
One hundred eyes of 100 Turkish patients were enrolled and equally randomized to
the MMC (27 women, 23 men; mean [SD} age, 47.0 [7.6} years) or control (26 wom-
en, 24 men; mean age, 46.6 [8.8} years) groups. The follow-up period was not
significantly different between the MMC and the control group (13.1 [1.l} months
vs 13.2 [1.4} months) (Table).
Significantly more eyes in the MMC group than the control group remained
symptom-free throughout the 1-year follow-up period (45/50 [90%} vs 33/50
[66%} of eyes; P = 0.005). Improvement in symptoms was achieved in significantly
fewer patients in the MMC group than the control group (3 [6%} vs 9 [l8%}; P <
0.005) at the 1-year follow-up visit. Significantly fewer eyes in the MMC group
than the control group remained symptomatic (excess tearing) (2/50 [4%} vs 8/50
[l6%}; P = 0.005). The success rate was significantly greater in the MMC group
than the control group (P < 0.005). Based on the patency of the drainage system,
the success rate was significantly greater in the MMC group than the control group
(48/50 [96%} vs 42/50 [84%}; P = 0.005). The remaining 2 patients in the MMC
group and 8 patients in the control group had nonpatency due to obstruction by
granulation tissue at the osteotomy site and underwent revision endoscopic lacrimal
surgery.
Table. Demographic and clinical characteristics of the study patients (N = 100).*
Characteristic
Age, y
Mean (SO)
Range
Sex, no. (%)
Female
Male
Duration of symptoms, mean (SO), mo
Duration of follow-up, mean (SO), mo
MMC Group
(n = 50)
47.0 (7.6)
34-64
27 (54)
23 (46)
9.2 (1.9)
13.1 (1.1)
Control Group
(n = 50)
46.6 (8.8)
32-62
26 (52)
24 (48)
8.5 (1.7)
13.2 (1.4)
MMC = mitomycin C.
*There were no statistically significant between-group differences.
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Neither local nor systemic AEs (eg, nasal or gastrointestinal irritation) associated
with MMC were reported. No patient experienced nasal bleeding, mucosal necrosis,
or infection during the follow-up period. No AEs were observed.
DISCUSSION
Studies evaluating success and complication rates of MMC treatment for chronic na-
solacrimal duct obstruction were found in the literature.4 In a prospective, random-
ized, controlled study in 88 eyes with primary acquired nasolacrimal duct obstruc-
tions, Liao et al4 assessed the efficacy of 0.2 mg/mL MMC applied to the osteotomy
site for 30 minutes in DCR surgery. During the lO-month follow-up period, 95.5%
(42/44) of patients in the MMC group were symptom-free, while 70.5% (31/44) of
control group patients were symptom-free (P < 0.05). Improvement in symptoms was
observed in 18% of patients during the follow-up period. The nonpatency rate in the
MMC group and the control group was 4.5% and 11.4%, respectively (P < 0.05).
Yeatts and Neves 13 reported patency of the nasolacrimal duct with external DCR and
MMC 0.3 mg/mL for 3 minutes during the 14.6-month follow-up period. They
evaluated the usefulness of a single intraoperative application of MMC in repeat DCR
for membranous failure and stated that adjunctive use of MMC might increase the
success rate of repeat DCR. In a study of intraoperative MMC with DCR, Kao et
allo found that the osteotomy site was significantly larger in the MMC group than
the control group (mean [SD}, 27.10 [5.78} vs 10.63 [3.371 mm2). Kao et al carried
out their study in 15 eyes of 14 patients diagnosed with primary acquired nasolacri-
mal duct obstruction. Patients were assigned randomly to either the MMC or the
control group. Surgical procedures in both groups were exactly the same, except that
in the patients in the MMC group, a piece of neurosurgical cottonoid soaked with
0.2 mg/mL MMC was applied to the osteotomy site and then removed transnasally
after 30 minutes. Endonasal findings were recorded at the completion of the surgery
and at 1, 3, and 6 months after surgery for the 2 groups. Intraoperative MMC was
effective in maintaining a larger osteotomy size. A statistically significant difference
was noted at 6 months (P < 0.05). Ugurbas et aI14 studied the histopathologic effects
of MMC on transnasal DCR by soaking the osteotomy site in MMC 0.5 mg/mL for
2.5 minutes. A 0.5-mg/mL solution of MMC was applied to the osteotomy site for
2.5 minutes intraoperatively. Specimens from 4 patients were collected during surgery
and at 15 days, 1 month, 3 months, and 6 months after surgery. The specimens were
examined under light and electron transmission microscopy and were compared with
control specimens. Light and electron microscopy found attenuated epithelium and
looser, hypocellular subepithelial connective tissue in the MMC specimens. This find-
ing suggests the efficacy of MMC application and indicates histopathologic evidence
of the procedure. MMC is considered to be effective in decreasing the density and
cellularity of mucosa and achieving higher success rates (improvement in tearing con-
dition and lesser fibrous tissue formation) in DCR surgery. This result corresponds with
the results of the study carried out by Yildirim et a1. 6
In our study, the 2 groups included the same number of eyes. There was no signifi-
cant difference in the mean ages of the patients in the 2 groups. Forty-five eyes in the
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MMC group and 33 eyes in the control group remained symptom-free throughout the
1-year follow-up period. Improvement in symptoms was achieved in 3 eyes in the
MMC group and 9 eyes in the control group. Based on the patency of the drainage
system, the success rate was significantly greater in the MMC group than the control
group. The remaining 2 patients in the MMC group and 8 patients in the control
group had nonpatency due to obstruction at the osteotomy site.
The effectiveness of intraoperative MMC treatment in DCR surgery was report-
ed by You and Fang. ls Fifty eyes were included in the study and were divided into
3 groups. MMC 0.2 and 0.5 mg/mL were administered for 5 minutes and the
results were compared with those of a conventional DCR surgery group. A signifi-
cant difference was found between the MMC-treated patients and the control group
in patency rate and osteotomy size; however, no significant difference was found
between the 2 MMC groups. Ugurbas et aI14 found that MMC 0.5 mg/mL for 5 and
2.5 minutes favorably affected healing at the osteotomy site. In our study, we ad-
ministered MMC 0.2 mg/mL for 30 minutes to maximize the inhibition of fibro-
sis. No significant increase in the duration of surgery was noted due to MMC
application.
Pterygium and glaucoma filtration surgeries are associated with some AEs (eg,
corneal ulcus or perforation, scleral calcification, secondary cataract, endophthalmitis,
hypotony, and maculopathy).l6,l7 We observed no serious AEs associated with MMC
administration, such as mucosal necrosis, abnormal nasal bleeding, severe infections,
or gastrointestinal bleeding. 3,lo
Limitations of this study were its small sample size and the lack of elderly patients
in the study population. Further large, double-masked, randomized studies are needed
to confirm these findings.
CONCLUSION
In the management of these patients with primary acquired nasolacrimal duct ob-
struction, adjunctive intraoperative MMC application with standard DCR surgery
had a significantly higher success rate than did standard DCR surgery alone.
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